Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 12/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12521472 | 0.87 | MAPK1 (0.48) | AAK1NPC1RAB9ARECQLSMN1; SMN2 | |
| SCHEMBL8139434 | 0.86 | AAK1 (0.46) | AAK1NPC1RAB9ARECQLSMN1; SMN2 | |
| SCHEMBL4923072 | 0.84 | AAK1 (0.45) | AAK1NPC1RAB9ARECQLSMN1; SMN2 | |
| SCHEMBL15261588 | 0.84 | AAK1 (0.50) | AAK1NPC1RAB9ARECQLSMN1; SMN2 | |
| SCHEMBL4930587 | 0.82 | AAK1 (0.48) | AAK1HTTFPR2 | |
| SCHEMBL30175900 | 0.81 | AAK1 (0.49) | AAK1NPC1RAB9ARECQLSMN1; SMN2 | |
| SCHEMBL1519234 | 0.81 | AAK1 (0.49) | AAK1NPC1RAB9ARECQLSMN1; SMN2 | |
| SCHEMBL5754824 | 0.81 | CNR2 (0.44) | AAK1NPC1RAB9ARECQLSMN1; SMN2 | |
| SCHEMBL27773448 | 0.80 | AAK1 (0.44) | AAK1NPC1RAB9ARECQLSMN1; SMN2 | |
| SCHEMBL24498563 | 0.79 | AAK1 (0.48) | AAK1NPC1RAB9ARECQLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194522-A1 | Development of Fluorogenic Substrates For Monoamine Oxidases (Mao-A and Mao-B) | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE | 2008-08-14 | — | — | US | disclosed |
| US-20080194522-A1 | Development of Fluorogenic Substrates For Monoamine Oxidases (Mao-A and Mao-B) | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE | 2008-08-14 | — | — | US | disclosed |
| US-20080194522-A1 | Development of Fluorogenic Substrates For Monoamine Oxidases (Mao-A and Mao-B) | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194522-A1 | Development of Fluorogenic Substrates For Monoamine Oxidases (Mao-A and Mao-B) | MAOA, MAOB, COMT | AAK1 2079/4885MTNR1A 454/4885MTNR1B 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.